Mepolizumab subcutaneous (SC) vs placebo
Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma
1 finding from 1 review
- no estimate extracted3 studies · 1231 participantsHigh
Findings
What do systematic reviews say?
2,234 questions · 2,325 findings · 216 reviews · Airways
No studies found 249 · 10.7%GRADE not reported 107 · 4.6%Very low 276 · 11.9%Low 751 · 32.3%Moderate 718 · 30.9%High 224 · 9.6%
Benralizumab subcutaneous (SC) vs placebo
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Benralizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.59 [0.52, 0.66]4 studies · 3112 participantsHigh
Benralizumab subcutaneous (SC) vs placebo
Rate of exacerbations requiring emergency department treatment or admission · people with asthma
Benralizumab subcutaneous (SC) probably leads to lower rate of exacerbations requiring emergency department treatment or… compared with placebo (moderate certainty).
1 finding from 1 review
- Rate ratio 0.68 [0.47, 0.98]2 studies · 1537 participantsModerate
Benralizumab subcutaneous (SC) vs placebo
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma
1 finding from 1 review
- no estimate extracted3 studies · 1541 participantsHigh
Benralizumab subcutaneous (SC) vs placebo
Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma
1 finding from 1 review
- no estimate extracted4 studies · 2791 participantsHigh
Benralizumab subcutaneous (SC) vs placebo
FEV1 · people with asthma
1 finding from 1 review
- no estimate extracted4 studies · 2786 participantsHigh
Benralizumab subcutaneous (SC) vs placebo
Serious adverse events · people with asthma
Benralizumab subcutaneous (SC) leads to lower serious adverse events compared with placebo (high certainty).
1 finding from 1 review
- Risk ratio 0.76 [0.62, 0.93]5 studies · 3304 participantsHigh
Benralizumab subcutaneous (SC) vs placebo
Clinically significant adverse events leading to discontinuation · people with asthma
Benralizumab subcutaneous (SC) leads to higher clinically significant adverse events leading to discontinuation compared with placebo (high certainty).
1 finding from 1 review
- Risk ratio 2.04 [1.03, 4.03]4 studies · 3253 participantsHigh
Mepolizumab subcutaneous (SC) vs placebo
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma
1 finding from 1 review
- no estimate extracted3 studies · 1231 participantsHigh
Mepolizumab subcutaneous (SC) vs placebo
FEV1 · people with asthma
1 finding from 1 review
- no estimate extracted3 studies · 1231 participantsHigh
Mepolizumab subcutaneous (SC) vs placebo
Serious adverse events · people with asthma
Mepolizumab subcutaneous (SC) showed no clear difference in serious adverse events compared with placebo (high certainty).
1 finding from 1 review
- Risk ratio 0.68 [0.46, 1.01]3 studies · 1231 participantsHigh
Mepolizumab subcutaneous (SC) vs placebo
Clinically significant adverse events leading to discontinuation · people with asthma
Mepolizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).
1 finding from 1 review
- Risk ratio 0.6 [0.19, 1.85]3 studies · 1231 participantsHigh
Mepolizumab intravenous (IV) vs placebo
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Mepolizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.53 [0.44, 0.64]3 studies · 751 participantsHigh
Mepolizumab intravenous (IV) vs placebo
Rate of exacerbations requiring emergency department treatment or admission · people with asthma
Mepolizumab intravenous (IV) leads to lower rate of exacerbations requiring emergency department treatment or… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.52 [0.31, 0.87]2 studies · 690 participantsHigh
Intervention not reported
Proportion of people with COPD diagnoses confirmed with spirometry · health professionals managing COPD
1 finding from 1 review
- Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary care 2022 · Cochrane Headline outcomes onlyno estimate extracted4 participantsVery low
Intervention not reported
Proportion of patients with COPD referred to, participating in or having completed pulmonary rehabilitation · health professionals managing COPD
1 finding from 1 review
- Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary care 2022 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 625 participantsLow
Intervention not reported
Proportion of patients with COPD prescribed respiratory medication consistent with recommended guidelines · health professionals managing COPD
1 finding from 1 review
- Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary care 2022 · Cochrane Headline outcomes onlyno estimate extracted12 studies · 52899 participantsLow
Intervention not reported
Proportion of patients with COPD vaccinated against influenza/pneumococcal infections · health professionals managing COPD
1 finding from 1 review
- Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary care 2022 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 6846 participantsModerate
Intervention not reported
HRQoL · health professionals managing COPD
1 finding from 1 review
- Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary care 2022 · Cochrane Headline outcomes onlyno estimate extracted12 studies · 6526 participantsLow
Intervention not reported
Frequency of COPD exacerbations · health professionals managing COPD
1 finding from 1 review
- Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary care 2022 · Cochrane Headline outcomes onlyno estimate extracted10 participantsLow